摘要
T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically aggressive hematological malignancy with high rates of disease relapse and a poor prognosis. Current guidelines do not recommend any specific treatments for these patients, and only allogeneic stem cell transplant, which is associated with potential risks and toxicities, is a curative therapy. Recent clinical trials showed that immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and CAR T therapies, are successful in treating hematologic malignancies. CAR T cells, which specifically target the B-cell surface antigen CD19, have demonstrated remarkable efficacy in the treatment of B-cell acute leukemia, and some progress has been made in the treatment of other hematologic malignancies. However, the development of CAR T-cell immunotherapy targeting T-cell malignancies appears more challenging due to the potential risks of fratricide, T-cell aplasia, immunosuppression, and product contamination. In this review, we discuss the current status of and challenges related to CAR T-cell immunotherapy for T-ALL and review potential strategies to overcome these limitations.
学科与关键词
- Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and DevelopmentsXu, Xinjie; Huang, Shengkang; Xiao, Xinyi; Sun, Qihang; Liang, Xiaoqian; Chen, Sifei; Zhao, Zijing; Huo, Zhaochang; Tu, Sanfang*; Li, Yuhua*Frontiers in Immunology, 2021, 11: 569117.被引 29
- Current state of CAR-T therapy for T-cell malignanciesLuo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*Therapeutic Advances in Hematology, 2022, 13: 20406207221143025.被引 6
- T-ALL Cells as Tool Cells for CAR T TherapyRen, Anqi; Zhao, Yuan; Zhu, Haichuan*Vaccines, 2023, 11(4): 854.被引 1
